Compositions and combinations for the treatment of angiogenesis diseases and disorders
AssigneeFeramda Ltd.
InventorBenjamin SREDNI
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions, combinations and methods for treating, reducing, ameliorating, alleviating, or inhibiting the progression of, angiogenesis diseases and disorders in a patient in need thereof (such as for example AMD), utilizing Te-containing compounds.
Claims21
A combination comprising at least one Te-containing compound having the formula I or II:
- wherein:
- each of t, u and v is independently 0 or 1;
- each of m and n is independently 0, 1, 2 or 3;
- Y is selected from the group consisting of ammonium, phsophonium, potassium, sodium and lithium;
- X is a halogen atom;
- and
- each of R1-R18 is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, carbonyl;
- alkylcarbonylalkyl, carboxyalkyl, acyl, amido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfinyl, sulfate, amine, aryl, heteroaryl, phosphate, phosphonate and sulfoneamido;
- and at least one angiogenesis inhibitor.
(canceled)
(canceled)
12-24. (canceled)
A method of treating an angiogenesis related condition, disease or disorder comprising administering to a patient in need thereof at least one Te-containing compound selected from
- wherein:
- each of t, u and v is independently 0 or 1;
- each of in and n is independently 0, 1, 2 or 3;
- Y is selected from the group consisting of ammonium, phsophonium, potassium, sodium and lithium;
- X is a halogen atom;
- and
- each of R1-R18 is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, carbonyl, alkylcarbonylalkyl, carboxyalkyl, acyl, amido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfinyl, sulfate, amine, aryl, heteroaryl, phosphate, phosphonate and sulfoneamido;
- wherein said patient has been previously treated with at least one angiogenesis inhibitor (i.e. prior to the administration of said Te-containing compound).
A method of treating an angiogenesis related condition, disease or disorder comprising administering to a patient in need thereof at least one Te-containing compound selected from
- wherein:
- each of t, u and v is independently 0 or 1;
- each of m and n is independently 0, 1, 2 or 3;
- Y is selected from the group consisting of ammonium, phsophonium, potassium, sodium and lithium;
- X is a halogen atom;
- and
- each of R1-R18 is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, carbonyl, alkylcarbonylalkyl, carboxyalkyl, acyl, amido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfinyl, sulfate, amine, aryl, heteroaryl, phosphate, phosphonate and sulfoneamido;
- wherein said patient is being treated with at least one angiogenesis inhibitor (i.e. during the administration of said Te-containing compound).
28-32. (canceled)
37-38. (canceled)
Dependencies are inferred from the claim text.